Lasalocid sodium
Based on 4 publication(s) in Google Scholar
Lasalocid sodium (Lasalocid sodium-A) is an antibacterial and anticoccidial agent that can be used as feed additives. Lasalocid sodium exhibits antitumor activity. Lasalocid sodium is orally active.
For research use only. We do not sell to patients.
- Purity: 99.03%
- CAS No.: 25999-20-6
- Formula: C34H53NaO8
- Molecular Weight:612.77
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Antibacterial Compound Library
HY-L049
-
Phenols Library
HY-L057
-
Orally Active Compound Library
HY-L061
-
Antibiotics Library
HY-L067
-
Antiparasitic Compound library
HY-L082
-
Microbial Metabolite Library
HY-L084
-
Anti-Cancer Natural Product Library
HY-L107
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Animal Drug Library
HY-L218
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Lasalocid sodium
MoreAll Antibiotic Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.8 μM
Compound: 1, Lasalocid
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23932361] |
| BALB/3T3 | IC50 |
7.35 μM
Compound: 1, Lasalocid
|
Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
|
[PMID: 23932361] |
| HeLa | EC50 |
2 μM
Compound: Lasalocid
|
Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 3 hrs prior to Stx1 addition and further incubated for overnight and subsequ
Inhibition of Escherichia coli Stx1 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation incubated with cells for 3 hrs prior to Stx1 addition and further incubated for overnight and subsequ
|
[PMID: 32648758] |
| HepG2 | EC50 |
17.8 μM
Compound: Lasalocid A Sodium
|
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
|
[PMID: 20966043] |
| HepG2 | IC50 |
>100 μM
Compound: 92124813
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
0.011 μM
Compound: 92124813
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| HT-29 | IC50 |
1.95 μM
Compound: 1, Lasalocid
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 23932361] |
| MCF7 | IC50 |
3.12 μM
Compound: 1, Lasalocid
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23932361] |
| P388 | IC50 |
4.54 μM
Compound: 1, Lasalocid
|
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
|
[PMID: 23932361] |
Lasalocid sodium (2.5 μg/mL) inhibits the growth of white spot bacteria, yellow spot bacteria, and fibrinolytic vibrio[1].
Lasalocid sodium works in the rumen by selectively promoting the growth of succinate-producing Bacteroides and S. ruminantium, which can lead to an increased formation of propionate in the rumen[1].
Lasalocid sodium (0-5 μM, 24-48 h) inhibits proliferations of cancer cells PC-3 and LNCaP, arrests the cell cycle at G0/G1 phase, induces apoptosis and autophagy in PC-3 cell[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pneumocystis carinii-infected rats models[3]
-
Dosage:5-20 mg/kg/day
-
Administration:po, administrated by food, 4 weeks
-
Result:Prevented P. carinii pneumonia.
Chemical Information
-
CAS No. 25999-20-6
-
Appearance Solid
-
Molecular Weight 612.77
-
Formula C34H53NaO8
-
Color White to yellow
-
SMILES
O=C(O[Na])C1=C(CC[C@@H](C)[C@H](O)[C@H](C)C([C@@H]([C@H]2O[C@@]([C@H]3CC[C@](O)(CC)[C@H](C)O3)(CC)C[C@@H]2C)CC)=O)C=CC(C)=C1O
-
Synonyms
Lasalocid-A sodium; Ionophore X-537A sodium; Antibiotic X-537A sodium
-
Structure Classification
-
Initial Source
Streptomyces lasaliensis
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Talanta
Fluorescence-activated cell sorting-based efficient screening of monensin monoclonal antibodies and applications in lateral flow immunoassay. [Abstract]2025 Apr 10:293:128128. PMID: 40222095 -
Langmuir
Lasalocid Acid Antibiotic at a Membrane Surface Probed by Sum Frequency Generation Spectroscopy. [Abstract]2020 Mar 31;36(12):3184-3192. PMID: 32069059 -
J Cancer
Lasalocid inhibits melanoma by down-regulating FOXM1 through PI3K/AKT and JNK/P38 MAPK pathways. [Abstract]2025 Jan 1;16(3):765-783. PMID: 39781349 -
Solvent & Solubility
DMSO : 100 mg/mL (163.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.08 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen M, et al. Effect of monensin and lasalocid-sodium on the growth of methanogenic and rumen saccharolytic bacteria. Appl Environ Microbiol. 1979 Jul;38(1):72-7. [Content Brief]
[2]. Kim KY, et al., Lasalocid induces cytotoxic apoptosis and cytoprotective autophagy through reactive oxygen species in human prostate cancer PC-3 cells. Biomed Pharmacother. 2017 Apr;88:1016-1024. [Content Brief]
[3]. OZ HS, et al., Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1997 Jan;41(1):191-2. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6319 mL | 8.1597 mL | 16.3193 mL | 40.7983 mL |
| 5 mM | 0.3264 mL | 1.6319 mL | 3.2639 mL | 8.1597 mL | |
| 10 mM | 0.1632 mL | 0.8160 mL | 1.6319 mL | 4.0798 mL | |
| 15 mM | 0.1088 mL | 0.5440 mL | 1.0880 mL | 2.7199 mL | |
| 20 mM | 0.0816 mL | 0.4080 mL | 0.8160 mL | 2.0399 mL | |
| 25 mM | 0.0653 mL | 0.3264 mL | 0.6528 mL | 1.6319 mL | |
| 30 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3599 mL | |
| 40 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0200 mL | |
| 50 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8160 mL | |
| 60 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6800 mL | |
| 80 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5100 mL | |
| 100 mM | 0.0163 mL | 0.0816 mL | 0.1632 mL | 0.4080 mL |
Powered by Bioz